Regeneron Pharmaceuticals, Inc. which can be found using ticker (REGN) have now 24 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $1,300.00 and $805.00 suggesting an average Analsyt target price of $1,164.39. Given that the stocks previous close was at $1,185.34 this would imply there is a potential downside of -1.8%. The 50 day MA is $1,081.09 while the 200 day moving average is $959.38. The total market capitalization for the company now stands at 130.91B. The price for the stock stands currently at: $1,187.53 USD
The potential market cap would be $128,593,313,251 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 31.41, revenue per share of $125.83 and a 7.61% return on assets.
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The Company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
